

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2011

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2011 (Unaudited)	Quarter ended 31.03.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
1 (a) Net Sales	2,763	2,514	10,850
(b) Other Operating Income	207	169	746
Total	2,970	2,683	11,596
2 Expenditure			
(a) (Increase)/Decrease in stock in trade and work in progress	(67)	(39)	(149)
(b) Consumption of raw materials	1,192	1,112	4,484
(c) Purchase of traded goods	236	188	1,055
(d) Employee cost	405	376	1,633
(e) Depreciation	54	43	197
(f) Other expenditure	562	513	2,396
(g) Total	2,382	2,193	9,616
3 Profit from Operations before Other Income and Interest (1-2)	588	490	1,980

Particulars	Quarter ended 31.03.2011 (Unaudited)	Quarter ended 31.03.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
4 Other Income	172	57	389
5 Profit before Interest (3+4)	760	547	2,369
6 Interest	2	-	29
7 Profit before tax and Exceptional items (5-6)	758	547	2,340
8 Tax Expense	252	186	790
9 Net Profit for the period before Exceptional items (7-8)	506	361	1,550
10 Exceptional item (net of tax)	-	-	757
11 Net Profit for the period after Exceptional items (9+10)	506	361	2,307
12 Paid-up equity share capital (Face Value of Rs. 10 per Share)	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year			9,748
14 Earnings Per Share (EPS) before Exceptional items (Rs.) (Basic and diluted EPS for the period and for the previous year) (Not Annualised)	22.00	15.70	67.39
15 Earnings Per Share (EPS) after Exceptional items (Rs.) (Basic and diluted EPS for the period	22.00	15.70	100.30

Particulars	Quarter ended 31.03.2011 (Unaudited)	Quarter ended 31.03.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
and for the previous year) (Not Annualised)			
16 Public Shareholding			
- Number of Shares	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60	39.60	39.60
17 Promoters and Promoter group Shareholding			
a) Pledged/Encumbered			
- Number of shares	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL
b) Non-encumbered			
- Number of shares	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%

Notes:

1. The above results were approved by the Board of Directors of the Company at its Meeting held on April 26, 2011.
2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2011
3. The Board of Directors had, at its Meeting held on February 16, 2011, recommended a Final dividend of Rs.23 per Equity share of Rs.10 for the year ended December 31, 2010 and a Special One-time Dividend of Rs.28 per Equity Share of Rs.10. The said dividend, if declared at the Annual General Meeting to be held on April 26, 2011, will be paid on May 2, 2011.
4. The break up of Net Sales is as follows:

Rs. Million

	Quarter ended March 31, 2011	Quarter ended March 31, 2010	Growth %
Domestic Sales-Others	2,221	1,972	12.6%
Export Sales	542	542	0.0%
Total Sales	2,763	2,514	9.9%

5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. Information on investor complaints is furnished below:

Pending as on Jan 1, 2011	Received during the quarter	Disposed of during the quarter	Pending as on Mar 31, 2011
Nil	1	1	Nil

7. The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR